Freenome, Inc. (FRNM) stock
FRNMNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.82−0.27 (-2.68%)
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Freenome r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $68.42M | – |
| Q3 FY2025 | Sep 30, 2025 | $50.63M | – |
See a number that looks wrong?